Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pembrolizumab - Merck & Co

Drug Profile

Pembrolizumab - Merck & Co

Alternative Names: Keytruda; Lambrolizumab; MK-3475; SCH-900475

Latest Information Update: 06 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co; The Leukemia & Lymphoma Society
  • Developer Aduro BioTech; AIO Studien gGmbH; Amgen; Augusta University; BerGenBio; Big Ten Cancer Research Consortium; BioLineRx; Canadian Cancer Trials Group; Celgene Corporation; Celleron Therapeutics; Centre Leon Berard; Columbia University; Dana-Farber Cancer Institute; DNAtrix; Duke University; Eisai Co Ltd; Eli Lilly and Company; Emory University; European Network of Gynaecological Oncological Trial Groups; Fox Chase Cancer Center; Genexine; Gilead Sciences; H. Lee Moffitt Cancer Center and Research Institute; Highlight Therapeutics; Hoosier Cancer Research Network; Icahn School of Medicine at Mount Sinai; ImmunoGen; Incyte Corporation; Institut fuer Frauengesundheit; Institute of Cancer Research; M. D. Anderson Cancer Center; Massachusetts General Hospital; Mayo Clinic; Memorial Sloan-Kettering Cancer Center; Merck & Co; Merck Sharp & Dohme; Moderna Therapeutics; National Cancer Center Hospital East; National Cancer Institute (France); National Cancer Institute (USA); Netherlands Cancer Institute; Northwestern University; NYU Langone Medical Center; Oslo University Hospital; Plexxikon; Providence Health & Services; Royal Marsden NHS Foundation Trust; Sarcoma Alliance for Research through Collaboration; Sellas Life Sciences Group; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Spanish Breast Cancer Research Group; Syndax Pharmaceuticals; TG Therapeutics Inc; University College London; University Health Network; University of Alabama; University of Birmingham; University of California at Los Angeles; University of California at San Francisco; University of California, San Diego; University of Colorado at Denver; University of Miami; University of Pittsburgh; University of Utah; University of Washington; Verastem Oncology; Wakayama Medical University; Washington University School of Medicine; Yale University
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Oesophageal cancer; Merkel cell carcinoma; Malignant melanoma; Follicular lymphoma; Liver cancer; Gastric cancer; Diffuse large B cell lymphoma; Hodgkin's disease; Nasopharyngeal cancer; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cervical cancer; Colorectal cancer; Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
  • Registered Bladder cancer; Cancer; Endometrial cancer; Merkel cell carcinoma; Oesophageal cancer; Renal cell carcinoma; Squamous cell cancer
  • Preregistration Adenocarcinoma; Breast cancer
  • Phase III Biliary cancer; Fallopian tube cancer; Gastrointestinal cancer; Mesothelioma; Multiple myeloma; Nasopharyngeal cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer
  • Phase II Acute myeloid leukaemia; Adenoid cystic carcinoma; Bone cancer; Brain metastases; Cholangiocarcinoma; Follicular lymphoma; Germ cell and embryonal neoplasms; Glioblastoma; Glioma; Inflammatory breast cancer; Liver metastases; Lymphoma; Malignant thymoma; Meningeal carcinomatosis; Meningioma; Myelodysplastic syndromes; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Osteosarcoma; Penile cancer; Rectal cancer; Recurrent respiratory papillomatosis; Sarcoma; Soft tissue sarcoma; Thyroid cancer; Uveal melanoma
  • Phase I/II Chronic lymphocytic leukaemia; Haematological malignancies; Leiomyosarcoma; Mantle-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Phase I Gliosarcoma
  • Preclinical Human papillomavirus infections

Most Recent Events

  • 05 Oct 2020 Aduro Biotech has been merged with Chinook Therapeutics to form Chinook Therapeutics
  • 29 Sep 2020 Merck Co and Ceylad Oncology entered in a collaboration for a phase Ib KEYNOTE-B79 trial
  • 21 Sep 2020 Efficacy and adverse event data from a phase III KEYNOTE-590 trial in Oesophageal cancer released by Merck
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top